Antibody data
- Antibody Data
- Antigen structure
- References [23]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 15-1278-41 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-CD127 Monoclonal Antibody (eBioRDR5), PE-Cyanine5, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The eBioRDR5 monoclonal antibody reacts with human CD127 (Interleukin-7 Receptor alpha). CD127 complexes with CD132, also known as the common gamma chain (gamma c), to form the multi-functional IL-7 receptor (IL-7R). CD127 is a type I glycoprotein with a molecular weight of 75-80 kDa and is expressed by immature B cells through the early pre-B stage, by thymocytes during several stages of their development, and on most mature T cells, with transient down-regulation upon activation. Binding of IL-7 results in signal transduction which occurs through several tyrosine kinase pathways including the Jak/STAT pathway. IL-7 is indispensible for the development of lymphocytes, and the control of homeostatic proliferation of T-cells in the periphery. In addition, IL-7R signaling is know to be involved in the regulation of T cell receptor (TCR) locus rearrangement in gamma delta T cells. Interestingly, recently it has been demonstrated that CD127 expression is down-regulated on CD4+CD25+ regulatory T cells (T regs). While the co-expression of CD4 and CD25 has become widely used as an indicator of T regs, this method of identification may also include cells without suppressive activity. It has clearly been shown that CD4+CD25+ cells that have down-regulated the expression of CD127 are significantly more highly-enriched for the regulatory T population, as defined by expression of the T reg-specific transcription factor Foxp3 and the suppressive activity of these cells, in vitro. Binding of the eBioRDR5 monoclonal antibody to PBMCs is blocked by pre-incubation of the cells with recombinant human IL-7 (cat. 14-8079). Applications Reported: This eBioRDR5 antibody has been reported for use in flow cytometric analysis. Applications Tested: This eBioRDR5 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.125 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Light sensitivity: This tandem dye is sensitive photo-induced oxidation. Please protect this vial and stained samples from light. Fixation: Samples can be stored in IC Fixation Buffer (cat. 00-8222) (100 µL cell sample + 100 µL IC Fixation Buffer) or 1-step Fix/Lyse Solution (cat. 00-5333) for up to 3 days in the dark at 4°C with minimal impact on brightness and FRET efficiency/compensation. Some generalizations regarding fluorophore performance after fixation can be made, but clone specific performance should be determined empirically. Excitation: 488-561 nm; Emission: 667 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- eBioRDR5
- Vial size
- 25 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references Characterization of CD127- CD25++ Treg from human colostrum.
ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells.
HDAC inhibition potentiates immunotherapy in triple negative breast cancer.
Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer.
Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis.
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.
Decreased T Follicular Regulatory Cell/T Follicular Helper Cell (TFH) in Simian Immunodeficiency Virus-Infected Rhesus Macaques May Contribute to Accumulation of TFH in Chronic Infection.
Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.
Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells.
Highly heterogeneous, activated, and short-lived regulatory T cells during chronic filarial infection.
The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study.
Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies.
Bet v 1-specific T-cell receptor/forkhead box protein 3 transgenic T cells suppress Bet v 1-specific T-cell effector function in an activation-dependent manner.
Interleukin-2 and regulatory T cells in graft-versus-host disease.
Uncoupling of proliferation and cytokines from suppression within the CD4+CD25+Foxp3+ T-cell compartment in the 1st year of human type 1 diabetes.
Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells.
Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells.
Allosuppressive donor CD4+CD25+ regulatory T cells detach from the graft and circulate in recipients after liver transplantation.
Loss of IL-7 receptor alpha on CD4+ T cells defines terminally differentiated B cell-helping effector T cells in a B cell-rich lymphoid tissue.
Loss of IL-7 receptor alpha on CD4+ T cells defines terminally differentiated B cell-helping effector T cells in a B cell-rich lymphoid tissue.
Cérbulo-Vázquez A, Hernández-Peláez G, Arriaga-Pizano LA, Bautista-Pérez P, Romero-Venado J, Flores-González JC, Figueroa-Damian R, Soriano-Becerril D, Mancilla-Herrera I
American journal of reproductive immunology (New York, N.Y. : 1989) 2018 Feb;79(2)
American journal of reproductive immunology (New York, N.Y. : 1989) 2018 Feb;79(2)
ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells.
Lecciso M, Ocadlikova D, Sangaletti S, Trabanelli S, De Marchi E, Orioli E, Pegoraro A, Portararo P, Jandus C, Bontadini A, Redavid A, Salvestrini V, Romero P, Colombo MP, Di Virgilio F, Cavo M, Adinolfi E, Curti A
Frontiers in immunology 2017;8:1918
Frontiers in immunology 2017;8:1918
HDAC inhibition potentiates immunotherapy in triple negative breast cancer.
Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN
Oncotarget 2017 Dec 26;8(69):114156-114172
Oncotarget 2017 Dec 26;8(69):114156-114172
Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer.
Su S, Liao J, Liu J, Huang D, He C, Chen F, Yang L, Wu W, Chen J, Lin L, Zeng Y, Ouyang N, Cui X, Yao H, Su F, Huang JD, Lieberman J, Liu Q, Song E
Cell research 2017 Apr;27(4):461-482
Cell research 2017 Apr;27(4):461-482
Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis.
Nguyen DX, Ehrenstein MR
The Journal of experimental medicine 2016 Jun 27;213(7):1241-53
The Journal of experimental medicine 2016 Jun 27;213(7):1241-53
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.
Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, Dusenbury K, Whangbo J, Nikiforow S, Alyea EP 3rd, Armand P, Cutler CS, Ho VT, Chen YB, Avigan D, Blazar BR, Antin JH, Ritz J, Soiffer RJ
Blood 2016 Jul 7;128(1):130-7
Blood 2016 Jul 7;128(1):130-7
Decreased T Follicular Regulatory Cell/T Follicular Helper Cell (TFH) in Simian Immunodeficiency Virus-Infected Rhesus Macaques May Contribute to Accumulation of TFH in Chronic Infection.
Chowdhury A, Del Rio Estrada PM, Tharp GK, Trible RP, Amara RR, Chahroudi A, Reyes-Teran G, Bosinger SE, Silvestri G
Journal of immunology (Baltimore, Md. : 1950) 2015 Oct 1;195(7):3237-47
Journal of immunology (Baltimore, Md. : 1950) 2015 Oct 1;195(7):3237-47
Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
Muraro E, Comaro E, Talamini R, Turchet E, Miolo G, Scalone S, Militello L, Lombardi D, Spazzapan S, Perin T, Massarut S, Crivellari D, Dolcetti R, Martorelli D
Journal of translational medicine 2015 Jun 27;13:204
Journal of translational medicine 2015 Jun 27;13:204
CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.
Hanley PJ, Melenhorst JJ, Nikiforow S, Scheinberg P, Blaney JW, Demmler-Harrison G, Cruz CR, Lam S, Krance RA, Leung KS, Martinez CA, Liu H, Douek DC, Heslop HE, Rooney CM, Shpall EJ, Barrett AJ, Rodgers JR, Bollard CM
Science translational medicine 2015 Apr 29;7(285):285ra63
Science translational medicine 2015 Apr 29;7(285):285ra63
Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells.
Gautron AS, Dominguez-Villar M, de Marcken M, Hafler DA
European journal of immunology 2014 Sep;44(9):2703-2711
European journal of immunology 2014 Sep;44(9):2703-2711
Highly heterogeneous, activated, and short-lived regulatory T cells during chronic filarial infection.
Metenou S, Coulibaly YI, Sturdevant D, Dolo H, Diallo AA, Soumaoro L, Coulibaly ME, Kanakabandi K, Porcella SF, Klion AD, Nutman TB
European journal of immunology 2014 Jul;44(7):2036-47
European journal of immunology 2014 Jul;44(7):2036-47
The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study.
Meijerink H, Indrati AR, van Crevel R, Joosten I, Koenen H, van der Ven AJ
BMC infectious diseases 2014 Dec 13;14:683
BMC infectious diseases 2014 Dec 13;14:683
Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.
Nikiforow S, Kim HT, Bindra B, McDonough S, Glotzbecker B, Armand P, Koreth J, Ho VT, Alyea EP 3rd, Blazar BR, Ritz J, Soiffer RJ, Antin JH, Cutler CS
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2013 May;19(5):804-11
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2013 May;19(5):804-11
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
Koreth J, Stevenson KE, Kim HT, McDonough SM, Bindra B, Armand P, Ho VT, Cutler C, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Alyea EP 3rd
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Sep 10;30(26):3202-8
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Sep 10;30(26):3202-8
A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies.
Muraro E, Martorelli D, Turchet E, Miolo G, Scalone S, Comaro E, Talamini R, Mastorci K, Lombardi D, Perin T, Carbone A, Veronesi A, Crivellari D, Dolcetti R
Breast cancer research : BCR 2011;13(6):R117
Breast cancer research : BCR 2011;13(6):R117
Bet v 1-specific T-cell receptor/forkhead box protein 3 transgenic T cells suppress Bet v 1-specific T-cell effector function in an activation-dependent manner.
Schmetterer KG, Haiderer D, Leb-Reichl VM, Neunkirchner A, Jahn-Schmid B, Küng HJ, Schuch K, Steinberger P, Bohle B, Pickl WF
The Journal of allergy and clinical immunology 2011 Jan;127(1):238-45, 245.e1-3
The Journal of allergy and clinical immunology 2011 Jan;127(1):238-45, 245.e1-3
Interleukin-2 and regulatory T cells in graft-versus-host disease.
Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ
The New England journal of medicine 2011 Dec 1;365(22):2055-66
The New England journal of medicine 2011 Dec 1;365(22):2055-66
Uncoupling of proliferation and cytokines from suppression within the CD4+CD25+Foxp3+ T-cell compartment in the 1st year of human type 1 diabetes.
Hughson A, Bromberg I, Johnson B, Quataert S, Jospe N, Fowell DJ
Diabetes 2011 Aug;60(8):2125-33
Diabetes 2011 Aug;60(8):2125-33
Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells.
Payne RP, Kløverpris H, Sacha JB, Brumme Z, Brumme C, Buus S, Sims S, Hickling S, Riddell L, Chen F, Luzzi G, Edwards A, Phillips R, Prado JG, Goulder PJ
Journal of virology 2010 Oct;84(20):10543-57
Journal of virology 2010 Oct;84(20):10543-57
Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells.
Nagata S, Ise T, Pastan I
Journal of immunology (Baltimore, Md. : 1950) 2009 Jun 15;182(12):7518-26
Journal of immunology (Baltimore, Md. : 1950) 2009 Jun 15;182(12):7518-26
Allosuppressive donor CD4+CD25+ regulatory T cells detach from the graft and circulate in recipients after liver transplantation.
Demirkiran A, Bosma BM, Kok A, Baan CC, Metselaar HJ, Ijzermans JN, Tilanus HW, Kwekkeboom J, van der Laan LJ
Journal of immunology (Baltimore, Md. : 1950) 2007 May 15;178(10):6066-72
Journal of immunology (Baltimore, Md. : 1950) 2007 May 15;178(10):6066-72
Loss of IL-7 receptor alpha on CD4+ T cells defines terminally differentiated B cell-helping effector T cells in a B cell-rich lymphoid tissue.
Lim HW, Kim CH
Journal of immunology (Baltimore, Md. : 1950) 2007 Dec 1;179(11):7448-56
Journal of immunology (Baltimore, Md. : 1950) 2007 Dec 1;179(11):7448-56
Loss of IL-7 receptor alpha on CD4+ T cells defines terminally differentiated B cell-helping effector T cells in a B cell-rich lymphoid tissue.
Lim HW, Kim CH
Journal of immunology (Baltimore, Md. : 1950) 2007 Dec 1;179(11):7448-56
Journal of immunology (Baltimore, Md. : 1950) 2007 Dec 1;179(11):7448-56
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with Anti-Human CD3 FITC (Product # 11-0037-42) and Mouse IgG1 K Isotype Control PE-Cyanine5 (Product # 15-4714-81) (left) or Anti-Human CD127 PE-Cyanine5 (right).Cells in the lymphocyte gate were used for analysis.